29
views
0
recommends
+1 Recommend
2 collections
    0
    shares

          The flagship journal of the Society for Endocrinology. Learn more

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Optimal body mass index for protecting middle-aged and elderly patients with fatty liver from future fractures

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          Previous studies have suggested that body mass index (BMI) should be considered when assessing the relationship between fatty liver (FL) and osteoporosis. The aim of this study was to investigate future fracture events in people with FL, focusing on the effect of BMI in both sexes.

          Methods

          This retrospective cohort study, spanning from 2011 to 2019, enrolled 941 people, including 441 women and 500 men, aged 50 years or older who underwent liver imaging (ultrasound, computed tomography, or magnetic resonance image) and dual-energy X-ray absorptiometry (for bone mineral density measurements). The study examined predictors of osteoporosis in both sexes and the effect of different ranges of BMI (18.5–24, 24–27, and ≥27 kg/m 2) on the risk of future fracture events in FL patients.

          Results

          The average follow-up period was 5.3 years for women and 4.2 years for men. Multivariate analysis identified age and BMI as independent risk factors of osteoporosis in both sexes. Each unit increase in BMI decreased the risk of osteoporosis by ≥10%. In both women and men with FL, a BMI of 24–27 kg/m 2 offered protection against future fractures, compared to those without FL and with a BMI of 18.5–24 kg/m 2.

          Conclusion

          The protective effect of a higher BMI against future fractures in middle-aged and elderly female and male patients with FL is not uniform and diminishes beyond certain BMI ranges.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: not found

          The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis

          Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and the leading cause of liver-related morbidity and mortality. We aimed to predict the burden of NAFLD by examining and estimating the temporal trends of its worldwide prevalence and incidence.
            • Record: found
            • Abstract: found
            • Article: not found

            Clinician’s Guide to Prevention and Treatment of Osteoporosis

            The Clinician’s Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
              • Record: found
              • Abstract: found
              • Article: not found

              Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics

              The obesity epidemic is closely associated with the rising prevalence and severity of nonalcoholic fatty liver disease (NAFLD): obesity has been linked not only with simple steatosis (SS), but also with advanced disease, i.e., nonalcoholic steatohepatitis (NASH), NASH-related cirrhosis and hepatocellular carcinoma. As a consequence, apart from increasing all-cause mortality, obesity seems to increase liver-specific mortality in NAFLD patients. Given the lack of approved pharmacological interventions for NAFLD, targeting obesity is a rational option for its management. As the first step, lifestyle modification (diet and exercise) is recommended, although it is difficult to achieve and sustain. When the first step fails, adding pharmacotherapy is recommended. Several anti-obesity medications have been investigated in NAFLD (e.g., orlistat, glucagon-like peptide-1 analogs), other anti-obesity medications have not been investigated (e.g., lorcaserin, phentermine hydrochloric, phentermine/topiramate and naltrexone/bupropion), whereas some medications with weight-lowering efficacy have not been approved for obesity (e.g., sodium-glucose cotransporter-2 inhibitors, farnesoid X receptor ligands). If the combination of lifestyle modification and pharmacotherapy also fails, then bariatric surgery should be considered in selected morbidly obese individuals. This review summarizes best evidence linking obesity with NAFLD and presents related therapeutic options.

                Author and article information

                Journal
                Endocr Connect
                Endocr Connect
                EC
                Endocrine Connections
                Bioscientifica Ltd (Bristol )
                2049-3614
                03 July 2024
                31 May 2024
                01 August 2024
                : 13
                : 8
                : e240089
                Affiliations
                [1 ]Department of Medical Education , Taipei Veterans General Hospital, Taipei, Taiwan
                [2 ]Faculty of Medicine , School of Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan
                [3 ]Department of Family Medicine , Taipei Veterans General Hospital, Taipei, Taiwan
                [4 ]Division of Musculoskeletal Section , Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan
                [5 ]Division of Allergy , Immunology, and Rheumatology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Foundation, Taipei, Taiwan
                [6 ]School of Medicine , College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan
                [7 ]Division of Gastroenterology and Hepatology , Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
                Author notes
                Correspondence should be addressed to Y-Y Yang: yangyy@ 123456vghtpe.gov.tw

                *(H-T H Wu and Y-Y Yang contributed equally to this work)

                Author information
                http://orcid.org/0000-0002-7719-0397
                Article
                EC-24-0089
                10.1530/EC-24-0089
                11227054
                38819306
                fe2d185a-9393-4529-b6b7-01ae3f604a19
                © the author(s)

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

                History
                : 02 March 2024
                : 31 May 2024
                Funding
                Funded by: Taipei Veterans General Hospital, doi http://dx.doi.org/10.13039/501100011912;
                Funded by: Ministry of Science and Technology, doi http://dx.doi.org/10.13039/501100003711;
                Categories
                Research
                EC-Bone-and-Mineral-Metabolism, Bone and Mineral Metabolism
                Custom metadata
                EC-Bone-and-Mineral-Metabolism

                fatty liver,osteoporosis,fracture,body mass index,bone mineral density

                Comments

                Comment on this article

                Related Documents Log